Linda Yaccarino’s subsequent position after departing X as CEO can be one other chief govt position at eMed Population Health, an AI startup constructing a tech platform for sufferers utilizing GLP-1s.
Yaccarino was a longtime promoting govt at NBCUniversal however left to hitch X as CEO for 2 years, the place she managed to have a positive impact on the social community’s troubled advert income mannequin, regardless of her and Elon Musk’s shared method to minimizing content material moderation.
Although Yaccarino doesn’t have expertise in well being tech, eMed stated in a press launch that they sought her out for her “simple means to barter new partnerships” — it definitely additionally helps that her tenure at X made her well-known within the tech world, drawing extra eyes towards the startup.
eMed previously produced a tech platform that was designed for use with at-home COVID-19 speedy antigen checks, guiding customers by means of the method of administering these checks correctly. Now eMed is concentrated on GLP-1s, the category of medication like Ozempic, which can be utilized for each weight administration and therapy of kind 2 diabetes.
“To be a frontrunner in immediately’s healthcare market, firms have to have a fearless tenacity that enables them to not solely develop, however to even be courageous sufficient to step ahead and redefine a whole business,” Yaccarino said in a press launch. “We’re very well-positioned to be that tenacious chief, striving towards our final aim of enhancing international healthcare outcomes by means of our groundbreaking providers and platforms.”
Trending Merchandise
